title: Immunoregulatory functions of VISTA.
abstract: Utilization of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest with the completion of clinical trials demonstrating efficacy. While the results of monotherapy treatments are compelling, there is increasing emphasis on combination treatments in an effort to increase response rates to treatment. One of the most recently discovered NCRs is VISTA (V-domain Ig-containing Suppressor of T cell Activation). In this review, we describe the functions of this molecule in the context of cancer immunotherapy. We also discuss factors that may influence the use of anti-VISTA antibody in combination therapy and how genomic analysis may assist in providing indications for treatment.
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Nowak
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: J Louise
authors.initials: JL
authors.lastname: Lines
authors.affiliation: Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Frederick S
authors.initials: FS
authors.lastname: Varn
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Jie
authors.initials: J
authors.lastname: Deng
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Sarde
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Rodwell
authors.initials: R
authors.lastname: Mabaera
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Anna
authors.initials: A
authors.lastname: Kuta
authors.affiliation: ImmuNext, Inc., Lebanon, NH, USA.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Le Mercier
authors.affiliation: Department of Biomedical Data Science and Department of Molecular and Systems Biology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Chao
authors.initials: C
authors.lastname: Cheng
authors.affiliation: Department of Microbiology and Immunology, Norris Cotton Cancer Center Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.
authors.forename: Randolph J
authors.initials: RJ
authors.lastname: Noelle
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060887:B7 Antigens / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D003131:Combined Modality Therapy; D016678:Genome; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060887:B7 Antigens; C000588758:VSIR protein, human
keywords: 
  VISTA
  ; PD-1H; cancer; immunotherapies